trending Market Intelligence /marketintelligence/en/news-insights/trending/fepecxrve0d1in5bklng5w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J, Arrowhead Pharmaceuticals sign $3.7B deal for gene silencing drugs

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

J&J, Arrowhead Pharmaceuticals sign $3.7B deal for gene silencing drugs

Johnson & Johnson has entered a $3.7 billion agreement to advance ARO-HBV, an RNA interference therapy being developed by Arrowhead Pharmaceuticals Inc. to treat hepatitis B.

The companies also agreed to develop and commercialize up to three additional RNA interference, or RNAi, drug candidates, as selected by J&J, using Arrowhead's proprietary TRiM platform. RNAi medicines can be used to silence genes that cause disease in the body.

In return, Arrowhead Pharmaceuticals will receive $175 million in an upfront payment as well as a $75 million equity investment from J&J, which will buy the company's shares at $23 each. Arrowhead is eligible to receive up to $1.6 billion in milestone payments tied to ARO-HBV, while $1.9 billion are linked to the option and licensing of the three additional target candidates.

Arrowhead is also eligible to receive royalties on the net sales of commercialized products under the collaboration.

J&J will receive an exclusive, worldwide license for ARO-HBV, which is being studied in a phase 1/2 clinical trial known as AROHBV1001 to treat patients with a chronic hepatitis B virus infection. J&J will be responsible for the clinical development and commercialization once the trial is complete.

Meanwhile, J&J is also responsible for funding the discovery and development of additional targets and will have the option to license such drug candidates from Pasadena, Calif.-based Arrowhead Pharmaceuticals once they are ready to be studied in clinical trials.

If the licensing option is exercised, Janssen will be fully responsible for further development of the therapies.

The deal is expected to close in the fourth quarter of 2018, subject to antitrust approvals in the U.S. and other customary closing conditions.